John L. Levitow Health Care Center in Rocky Hill, CT

John L. Levitow Health Care Center is a medicare and medicaid certified nursing home in Rocky Hill, Connecticut. It is located in Hartford county at 287 West St, Rocky Hill, Connecticut 06067. You can reach out to the office of John L. Levitow Health Care Center via phone at (860) 616-3700. This skilled nursing facility has 125 federally certified beds with average occupancy rate of 64.96%. Its legal business name is State Of Connecticut and has the following ownership type - Government - State.

John L. Levitow Health Care Center (Medicare CCN 075443) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2020 (4 years certified) and the last quality survey was conducted in January, 2020.

Name	John L. Levitow Health Care Center
Location	287 West St, Rocky Hill, Connecticut
Certified By	Medicare and Medicaid
No. of Certified Beds	125
Occupancy Rate	64.96%
Medicare ID (CCN)	075443
Legal Business Name	State Of Connecticut
Ownership Type	Government - State

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with John L. Levitow Health Care Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1205951662
Organization Name	STATE OF CONNECTICUT
Doing Business As	DEPARTMENT OF VETERANS' AFFAIRS, VETERANS HOME
Address	287 West Street, Rocky Hill, CT 06067
Phone Number	860-616-3637

News Archive

National Covid-19 Resilience Programme in the UK would support older people through pandemic

Public health agencies across the UK should launch a National Covid-19 Resilience Programme to support older people through the pandemic and to keep them healthy and resilient over the winter - that's the recommendation from a leading group of scientists and clinicians working in the fields of physiology, nutrition and physiotherapy.

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

Galapagos NV issues new shares

Galapagos NV (Euronext: GLPG) announced today a capital increase of EUR 902,564 and the issue of 225,641 new shares as a result of the exercise of warrants by Galapagos warrant holders, including CEO Onno van de Stolpe.

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

Read more Medical News

› Verified 7 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for John L. Levitow Health Care Center are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care John L. Levitow Health Care Center give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

National Covid-19 Resilience Programme in the UK would support older people through pandemic

Public health agencies across the UK should launch a National Covid-19 Resilience Programme to support older people through the pandemic and to keep them healthy and resilient over the winter - that's the recommendation from a leading group of scientists and clinicians working in the fields of physiology, nutrition and physiotherapy.

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

Galapagos NV issues new shares

Galapagos NV (Euronext: GLPG) announced today a capital increase of EUR 902,564 and the issue of 225,641 new shares as a result of the exercise of warrants by Galapagos warrant holders, including CEO Onno van de Stolpe.

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

Read more Medical News

› Verified 7 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	0
Total Amount of Fines in Dollars	$0
Number of Payment Denials	0
Total Number of Penalties	0

The resident survey data of John L. Levitow Health Care Center is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	18.58	14.46
Percentage of long-stay residents who lose too much weight	4.58	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	34.4	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	5.13	1.79
Percentage of long-stay residents with a urinary tract infection	0.76	2.65
Percentage of long-stay residents who have depressive symptoms	0.46	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	2.5	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	100	93.87
Percentage of long-stay residents who received an antipsychotic medication	27.04	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	92.59	83.88